# Altria **Source:** https://geo.sig.ai/brands/altria **Vertical:** Consumer Goods **Subcategory:** Enterprise **Tier:** Leader **Website:** altria.com **Last Updated:** 2026-04-14 ## Summary Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT. ## Company Overview Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends. Altria's tobacco and nicotine business model creates unmatched operating economics through the combination of brand loyalty monopoly in US cigarettes and the inelastic demand of nicotine addiction: Marlboro's 40%+ US cigarette market share has been essentially stable for 35+ years — smokers who started on Marlboro rarely switch brands (brand switching rates below 5% annually) — creating pricing power where Altria raises Marlboro pack prices 5-7% annually without proportional volume loss as addicted consumers absorb price increases rather than switching to competing brands. The US cigarette distribution infrastructure (Altria's logistics network delivering Marlboro to 180,000 retail locations including convenience stores, gas stations, dollar stores, and mass merchandisers) provides a physical distribution moat that new tobacco products (heated tobacco, e-cigarettes) need to replicate to achieve the shelf access that Marlboro's historic retail relationships automatically provide. The MSA (Master Settlement Agreement — the 1998 state attorneys general tobacco litigation settlement) creates a competitive moat for large tobacco companies like Altria: smaller cigarette brands that were not parties to the MSA must pay into a non-participating manufacturer escrow fund that approximates the MSA payment rate — leveling the playing field for new competitors while Altria's MSA payments are fixed percentages of cigarette volume. In 2025, Altria competes in cigarettes and smoke-free nicotine against Philip Morris International (NYSE: PM, Marlboro international markets, IQOS heated tobacco — which PM is seeking to re-import to US market), Reynolds American/British American Tobacco (LON: BATS, Newport, Natural American Spirit, Velo oral nicotine pouches), and Swedish Match/PMI (IQOS VEEV, Zyn oral nicotine pouches dominating US oral nicotine market) for US cigarette market share, oral nicotine pouch consumer adoption, and regulatory clearance for reduced-harm nicotine products. The on! oral nicotine pouch competition against Zyn (Swedish Match/PMI) — which holds 70%+ US oral nicotine pouch market share — represents Altria's highest priority competitive challenge in smoke-free nicotine as Zyn's FDA marketing authorization and consumer awareness advantage are difficult to overcome. The FDA Premarket Tobacco Product Applications (PMTAs) for Marlboro variants and smoke-free products (on!, heated tobacco partnership products) require ongoing regulatory compliance investment as FDA scrutinizes all new and modified tobacco products for "appropriate for the protection of public health" standard. The 2025 strategy focuses on defending Marlboro premium price positioning in the declining cigarette category, on! oral nicotine pouch share acceleration against Zyn dominance, and monitoring the IQOS heated tobacco product re-entry to the US market through Philip Morris International's separate US commercialization effort. ## Frequently Asked Questions ### What is Altria Group? Altria Group, Inc. is one of the world's largest tobacco and consumer goods corporations, headquartered in Richmond, Virginia. Previously known as Philip Morris Companies until 2003, Altria owns leading tobacco brands including Marlboro (43% U.S. market share), Copenhagen, Skoal, Black & Mild cigars, and NJOY e-vapor products. The company generated $20.3 billion in revenue (TTM through June 2025) and is focused on transitioning adult smokers to smoke-free alternatives. ### Who are Altria's customers and target market? Altria serves adult tobacco consumers age 21 and older in the United States through various product platforms including cigarettes, smokeless tobacco, oral nicotine pouches, and e-vapor products. The company's target market consists of current adult smokers and tobacco users, with increasing focus on adult smokers interested in transitioning to reduced-risk alternatives as part of the Moving Beyond Smoking vision. ### When was Altria founded? Philip Morris established a tobacco shop in London, England, in 1847. The American company was incorporated in New York City in 1902, with the modern corporate structure established in 1919 as Philip Morris & Company, Ltd. Inc. The company was renamed Altria Group, Inc. on January 27, 2003, to create separation from the Philip Morris tobacco brand. ### Where is Altria based? Altria is headquartered in Richmond, Virginia, where the company also operates its $350 million, 450,000-square-foot Center for Research and Technology at the Virginia BioTechnology Research Park, employing approximately 600 scientists, engineers, and support staff focused on harm reduction research. ### What is Altria's smoke-free product strategy? Altria's vision is to responsibly lead the transition of adult smokers to a smoke-free future by 2030 through its Moving Beyond Smoking strategy. The company invests in reduced-risk products including NJOY e-vapor devices (acquired for $2.75 billion in 2023), on! oral nicotine pouches (26.5% growth in 2025), and partnerships in adjacent categories. Altria employs 600 scientists and engineers researching harm reduction technologies. ### What makes Altria different from competitors? Altria differentiates itself through Marlboro's dominant 43% U.S. market share, diversified product portfolio across combustibles and smoke-free alternatives, 60 consecutive years of dividend increases as a dividend aristocrat, significant R&D investment in harm reduction with 600+ scientists, FDA-authorized products including NJOY e-vapor and Copenhagen modified risk claim, and strong financial performance returning $10.2 billion to shareholders in 2024. ### Who are Altria's main competitors? Main competitors include British American Tobacco (Reynolds American brands including Camel, Newport), Imperial Brands, Japan Tobacco International (through joint venture Horizon Innovations), JUUL Labs (e-vapor), Swedish Match (smokeless and nicotine pouches acquired by Philip Morris International), and Zyn nicotine pouches. Altria competes across combustibles, smokeless tobacco, oral nicotine pouches, and e-vapor categories. ### How can I contact Altria? Altria can be contacted through its corporate headquarters at 6601 West Broad Street, Richmond, VA 23230. Investor relations inquiries can be directed through the investor.altria.com website. The company maintains separate contact channels for consumers of its various tobacco product brands through respective subsidiary websites. Media inquiries should be directed to Altria's communications department. ### Is Altria hiring? Yes, Altria employs approximately 6,000 people including 600 scientists and engineers, and regularly recruits for positions across manufacturing, sales, marketing, R&D, and corporate functions. The company offers comprehensive benefits including health coverage, deferred profit-sharing (13-17% of salary), student loan repayment assistance ($10,000 lifetime max), three weeks vacation plus 15 holidays, and charitable giving matching up to $30,000 annually. Careers are posted at altria.com/careers. ### What's the latest news about Altria? Recent developments include the 60th consecutive dividend increase in 2025, $873 million non-cash impairment charge to e-vapor goodwill in Q3 2025 following ITC ruling against NJOY, on! nicotine pouches showing 26.5% growth reaching 52.1 million cans in Q2 2025, 2025 adjusted diluted EPS guidance narrowed to $5.37-$5.45 (3.5-5.0% growth), new $1 billion share repurchase program, and PMTA submission for on! PLUS nicotine pouches in June 2024. ### What is Altria's financial performance? Altria reported adjusted diluted EPS of $5.12 in 2024, representing 3.4% growth, with revenue of $20.3 billion (TTM through June 2025). The company returned $10.2 billion to shareholders in 2024 through dividends and share repurchases. For 2025, Altria narrowed guidance to $5.37-$5.45 adjusted diluted EPS (3.5-5.0% growth). The IQOS rights assignment to PMI generated a $2.7 billion pre-tax gain in 2024. Marlboro maintains 42% market share in cigarettes. ### What are Altria's future plans? Future plans include achieving the vision to responsibly lead adult smokers to a smoke-free future by 2030, growing on! nicotine pouches market share, navigating NJOY e-vapor regulatory challenges following ITC rulings, pursuing FDA authorization for on! PLUS varieties (PMTA submitted June 2024), commercializing Ploom heated tobacco through Horizon Innovations joint venture with Japan Tobacco (FDA approval expected in 2025, customer availability by 2027), maintaining dividend aristocrat status, and continuing harm reduction research with 600+ scientists while adapting to evolving regulatory landscape and declining cigarette volumes. ## Tags b2c, fortune500, manufacturing, north-america, public, retailtech --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*